tbuckley/cabot-search huggingface dataset:
Abstract 15967: Risk of Ventricular Tachyarrhythmias Following Ejection Fraction Improvement in Patients With Implantable Cardiac Defibrillators Implanted for Primary Prevention of Sudden Cardiac Death
Authors: Jayasree Pillarisetti, Rakesh Gopinathannair, Matthew Haney, Madhu Reddy, Sandeep Reddy, Mehdi Khalafi, Arun Kanmantha Reddy, Niveditha Adabala, Vivek Yarlagadda, Sudharani Bommana, Dhanunjaya Lakkireddy
Journal: Circulation (2014)

Introduction: In patients who undergo cardiac device (ICD) implantation for primary prevention of sudden cardiac death (SCD), data is unclear if their generator needs to be replaced at end of life if their ejection fraction improves. Despite improvement in EF however, the underlying scar may remain the same. Methods: A retrospective study was performed at two high volume centers. Data on 280 patients who underwent ICD implantation for primary prevention of SCD was obtained after excluding patients with incomplete follow-up data. These patients were followed until November 2013 for any improvement in EF and if they underwent a generator change at device ERI. All arrhythmic events and appropriate and inappropriate shocks/ATP were all recorded. Mortality records were obtained from social security death index and chart review. Results: Thirty percent (n=86/280) of patients improved their EF to &gt; 35% of which 41% (n=36) underwent a generator change by the study ending period for ERI/lead malfunction/infection issues with the rest not yet at ERI. Mean baseline EF in patients with and without EF improvement was 26±7% and 23±7%, p=0.2. Data for arrhythmic events was unavailable in n=25 patients in those with EF improvement and n =39 patients in those without EF improvement. Among the remaining 61 patients, appropriate events (shock+ATP) were noted in 22% of patients (n=14/61) and inappropriate shocks and ATP in 6% of (n=4/61) patients after their EF improved to &gt; 35%. Two patients received a prior shock when their EF was low. In contrast, in patients who had no improvement in EF, 31% (n=48/155) received an appropriate event (p=&lt;0.01) while 14% (n=22/155) (p&lt;0.02) received inappropriate shocks and ATP. All-cause mortality in patients without subsequent improvement in EF versus those with EF improvement (38% vs. 17% (p=.006). Mean time to EF improvement was 44±35 months and mean duration of follow-up since EF improvement was 38±27 months. Conclusions: Although patients with improvement in EF had fewer total events (ATP+shock) than those without improvement, the percentage of patients with ICD therapy post EF improvement with no prior ICD discharges is high enough (20%, n=12/59) to warrant an ICD despite EF improvement.
Greek Medicine in Rome. The Fitzpatrick Lectures on the History of Medicine, Delivered at the Royal College of Physicians of London in 1909-1910, with other Historical Essays.
Authors: T. Clifford Allbutt
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Analysis of the surveillance situation for viral encephalitis and meningitis in Europe
Authors: O Donoso Mantke, A Vaheri, H Ambrose, M Koopmans, F de Ory, H Zeller, K Beyrer, A Windorfer, M Niedrig, None representing the European Network f
Journal: Eurosurveillance (2008)

Infective processes in the brain, spinal cord and meninges are considered to be the main causes of encephalitis, myelitis and meningitis. However, most cases remain unexplained. The incidence of different viral aetiologies (zoonotic and non-zoonotic) is especially poorly estimated, due to the lack of a standard case definition and of agreed diagnostic algorithms, including harmonised diagnostic methods and sample collection. It is important to clarify the incidence of viral encephalitis/meningitis and to optimise the diagnosis of infectious neurological illness, particularly to ensure early recognition of outbreaks or emerging infections such as West Nile encephalitis. The European Network for Diagnostics of 'Imported' Viral Diseases (ENIVD) has analysed the present surveillance situation for viral encephalitis/meningitis in Europe. Here we give an overview of the existing epidemiological sources of information in European Union (EU) Member States, mapping the laboratory capacity and identifying key requirements for a possible future surveillance study at European level. The data presented will help design a harmonised/standardised Europe-wide surveillance study investigating patients with encephalitis and/or meningitis in order to obtain more information on the role of infections in these rarely analysed syndromes, both from a clinical and an epidemiological perspective. .
665. Enhanced Transgene Delivery to Activated Vascular Endothelial Cells In Vitro and In Vivo Using a Novel Strategy To Modify Adenovirus Tropism
Authors: Yosuke Kawakami, Sergei M. Danilov, Paul N. Reynolds, Jessica M. Grunda, Michael Passineau, Irina V. Balyasnikova, Joel N. Glasgow, Minghui Wang, Zen-Bian Zhu, Pierre L. Triozzi, Wayne A. Aldrich, Jerry L. Blackwell, David T. Curiel
Journal: Molecular Therapy (2004)

The use of dendritic cells (DC) loaded with tumor-associated antigens (TAA) for therapeutic cancer vaccines is particularly attractive because of the central role that DCs play in immunity as antigen presenting cells (APCs). Efficient and specific loading of the DCs with TAA genes is needed for therapeutic cancer vaccines to be successful. Defining ways to target DCs would potentially lesson the amount of vector needed for an effective dose, decrease adverse reactions and/or damage to healthy cells, and lower production costs. DCs are extremely refractory to Ad infection due to the low levels of the primary Ad receptor, coxsackievirus-adenovirus receptor (CAR) on their surface. In this regard, we have successfully augmented the transduction of DCs by re-routing the Ad vector to CD40 that is expressed at relatively high levels on the DC surface. Angiotensin-converting enzyme (ACE), a zinc-metalloprotease with broad substrate specificity, is generally known as an important regulator of blood pressure, fluid, and electrolyte homeostasis. We have also reported a high level of ACE expression in DCs [Danilov, 2003, Exp. Hematol, 31: 1301]. Therefore, we evaluated adenovirus (Ad) targeting of human monocyte-derived DCs via the angiotensin-converting enzyme (ACE, CD143) surface marker. Surface and mRNA expression of ACE were analyzed by flow cytometry and real time PCR, then compared to that of CD40, a well-characterized DC marker. Targeting proteins were developed that have two binding specificities. One part of the targeting protein binds to the fiber of the Ad vector and the other part binds to the ACE expressed on the surface of DCs. Ad vectors were then complexed with the targeting proteins. The resulting ACE-targeted Ad was then used to infect human monocyte-derived DCs. We screened transductional and transcriptional activity of ACE-targeted adenovirus that has luciferase reporter genes under the control of the cytomegarovirus promoter in ΔE1 region (AdCMVLuc) in vitro. ACE surface expression levels were greater than CD40 levels in immature DCs (iDC), however, were less in mature DCs (mDC). The results of luciferase assay demonstrated that ACE-targeting significantly (4-fold) increased the Ad transduction efficiency of iDCs compared to untargeted Ad. This vector approach may thus mediate not only high efficiency gene delivery but also serve a proactive role in DC activation. These results illustrate a novel surface marker on DCs that may be utilized for the therapeutic cancer vaccines.
UPPER LOBE PNEUMONIA IN THE ADULT
Authors: Milton B. Rosenblatt, Arnold Bachman
Journal: Annals of Internal Medicine (1938)

Article1 April 1938UPPER LOBE PNEUMONIA IN THE ADULTMILTON B. ROSENBLATT, M.D., ARNOLD BACHMAN, M.D.MILTON B. ROSENBLATT, M.D.Search for more papers by this author, ARNOLD BACHMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-11-10-1845 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPneumonia of the upper lobes is neither a new nor a rare occurrence. It was described by Laennec and also by his contemporaries, Andral and Broussais. However, despite the common knowledge of its existence there have been exceedingly few references to this subject in the literature. This is equally true of the standard textbooks which deal very extensively with the general subject of pneumonia. It is not difficult to fathom the cause of this apparent neglect. The diagnosis of apical pneumonia by physical signs, alone, is attended with great difficulty and, in the absence of routine roentgenograms, the number of...References1. ADAMS FD: Some clinical observations on lobar pneumonia, New England Jr. Med., 1928, cxcix, 402-409. CrossrefGoogle Scholar2. MACCORDICK AH: A statistical review of 525 cases of lobar pneumonia, Canad. Med. Assoc. Jr., 1931, lx, 704. Google Scholar3. WARRALPERIN DSJ: Lobar pneumonia, ANN. INT. MED., 1933, vi, 1474-1488. LinkGoogle Scholar4. NORRISLANDIS GH: Diseases of the chest, 4th ed., 1929, W. B. Saunders Co., Philadelphia, p. 481. Google Scholar5. LEPAGE R: La pneumonie du sommet chez l'adulte, Bruxelles Med., 1928, viii, 1337-1343. Google Scholar6. SANTE LR: A study of lobar pneumonia and its complications, Am. Jr. Roentgenology, 1923, x, 351-366. Google Scholar7. HART AL: The postpneumonic lung, Am. Jr. Roentgenology, 1931, xxvi, 371-396. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication October 9, 1936.From the Second Medical Service of the City Hospital, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHigh Lung Cancer Incidence in Heavy Smokers Following Hospitalization due to Pneumonia 1 April 1938Volume 11, Issue 10Page: 1845-1855KeywordsMedical servicesPneumonia Issue Published: 1 April 1938 PDF downloadLoading ...
BMJ Christmas revue
Authors: R. Smith
Journal: BMJ (2001)

Last year we held the first ever BMJ Christmas revue, and it was a huge success. Phil Hammond, the compere, was on devastating form, teasing mercilessly a cabinet minister who was brave enough to turn up. Many of the sketches were both witty and acutely observed: the word revalidation will forever make me think of a faltering pianist being …
TV: Learning to be you
Authors: A. Furedi
Journal: BMJ (1999)

Remaining programmes (for 9-11 year olds), BBC 2, Tuesdays at 12 pm, 2 to 16 November

Ihave never understood why the idea of starting to educate young people about sex from the earliest years of their life provoked such a hysterical reaction from so many social commentators. Motherhood has only reinforced my view that it makes sense to answer children's questions about their bodies and their origins simply, factually, and truthfully. But then perhaps I have been let off the hook by an excellent nursery and a delightfully down-to-earth pregnant friend The nursery, faced with the first second-time around pregnant mum, was totally up front about the fact that Sophie's mum had a baby in her tummy. And my friend was sufficiently self confident to field a 3 year old's quiz about her bump. “How does it get out?” “It will be born.” “How is it born?” “It will come out between my legs.” “Where?” “Through a special hole.” “Wow, have I got one?” “No, only women have them—you have a willy instead.”

Sex is a part of life, and it makes sense to treat …
Differentiation of a human eosinophilic leukemia cell line (EoL-1) by a human T-cell leukemia cell line (HIL-3)-derived factor
Authors: M Morita, H Saito, T Honjo, Y Saito, S Tsuruta, KM Kim, M Tanaka, KJ Mori, M Mayumi, H Mikawa
Journal: Blood (1991)
THE ACUTE AND SUBACUTE PULMONARY INVOLVEMENT IN RHEUMATIC FEVER WITH NOTES ON THE COMPLICATION OF BASAL PULMONARY COLLAPSE
Authors: BENJAMIN A. GOULEY
Journal: Annals of Internal Medicine (1937)

ExcerptThere has been in recent years a renewed interest in the pulmonary lesions of rheumatic fever. Rabinowitz1 (1926), basing his opinion upon clinical data, felt that there was a distinct rheumatic pneumopathy. In conjunction with Eiman, in 1927, we described certain previously unrecorded gross and histologic pulmonary lesions occurring in rheumatic fever,2 and we elaborated upon these in 1932.3 We concluded that pulmonary involvement in rheumatic fever was common and the changes specific. In the meantime, other reports appeared in England (Naish, 19284; Fraser,5 1930), based on independent observations and with similar conclusions.We judge by the references that come...
Primary lymphoedema associated with xanthomatosis, vaginal lymphorrhoea and intestinal lymphangiectasia
Authors: E. Karg, C. Bereczki, J. Kovacs, I. Korom, A. Varkonyi, P. Megyeri, S. Turi
Journal: British Journal of Dermatology (2002)

Journal Article Primary lymphoedema associated with xanthomatosis, vaginal lymphorrhoea and intestinal lymphangiectasia Get access E. Karg, E. Karg Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Eszter Karg. E‐mail: karg@pedia.szote.u‐szeged.hu Search for other works by this author on: Oxford Academic Google Scholar C. Bereczki, C. Bereczki Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar J. Kovacs, J. Kovacs Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar I. Korom, I. Korom Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar A. Varkonyi, A. Varkonyi Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar P. Megyeri, P. Megyeri Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar S. Turi S. Turi Departments of Paediatrics and Dermatology, University of Szeged, Albert Szent‐Györgyi Medical School, PO Box 471, H‐6721 Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 146, Issue 1, 1 January 2002, Pages 134–137, https://doi.org/10.1046/j.1365-2133.2002.04477.x Published: 01 January 2002 Article history Accepted: 13 July 2001 Published: 01 January 2002
ECG criteria for BBB.
Authors: B Dabrowska
Journal: Circulation (1977)

ECG Criteria for BBBTo the Editor:The normal interval V-RVA observed by Sung et al. (Circulation 54: 442, 1976) in all but one case with surgically-induced patterns of RBBB without LAD suggests that these recordings were indeed patterns of incomplete right bundle branch block (RBBB).It is noteworthy that duration of QRS complexes was 120 msec in six cases and 125 or 130 msec in another four from 1 1 cases with RBBB without LAD patterns.The fact that the QRS complex in cases of incomplete bundle branch block may last as long as 120 msec was supported also b) investigations concerning incomplete RBBB,3 left fascicular blocks2 and incomplete LBBB.3These data suggest that criteria of NYHA and those of others for the diagnosis of bundle branch block should be revised.It seems the QRS duration should exceed at least 120 msec for the correct diagnosis of complete bundle branch block and for clear differen- tiation from incomplete bundle branch block.
973. Efficient Transduction of Bone Marrow-Derived Mesenchymal Stem Cells for Cancer Gene Therapy Using a Tropism-Modified Adeno-Associated Virus (AAV) Vector
Authors: Brett M. Hall, Amy E. Henning, Jeffrey S. Bartlett
Journal: Molecular Therapy (2004)

Top of pageAbstract
Exogenously administered bone marrow-derived mesenchymal stem cells (MSCs) will preferentially engraft at tumor sites and contribute to the population of stromal fibroblasts. This has allowed the development of therapeutic strategies based on the local production of biological agents by gene-manipulated MSCs following transplantation. Adeno-associated virus (AAV) - based vectors are attractive for the introduction of therapeutic genes into MSCs due to their ability to promote stable gene expression in the absence of integration. While there are currently at least 8 naturally occurring serotypes of AAV, the AAV2 serotype has been associated with most gene therapy studies to date. Previously, our laboratory has generated a novel recombinant AAV vector based on AAV2 that contains an “RGD” polypeptide sequence (4C-RGD) inserted into the AAV capsid protein(s) following VP1 amino acid 588, “rAAV2(RGD)”. As with many of the available non-viral transfection methods, we found that AAV serotypes 1, 2, and 5 poorly infect human MSCs, even at very high multiplicities of infection (MOI). In contrast, rAAV2(RGD) is able to transduce greater than 80% of human MSCs in vitro. This represents a nearly three-order of magnitude enhancement in gene transfer efficiency compared to unmodified AAV2-based vectors. One potential obstacle to AAV-mediated gene therapy is the prolonged delay in transgene expression following AAV infection in vivo. Our ex vivo gene therapy approach circumvents this delay as demonstrated by rAAV2(RGD)-mediated transgene expression in as little as 72 hours post-infection in infected MSCs. Importantly, rapid onset of transgene expression was achieved in the absence of adenoviral help and in conjunction with increasing MOIs of rAAV2(RGD). Characterization of AAV-transduced MSCs for tri-lineage differentiation potential (adipogenic, chondrogenic, and osteogenic), duration of transgene expression, and maintenance of transgene expression levels in vitro following rAAV2(RGD) infection is ongoing.

With the demonstration that human bone marrow-derived MSCs engraft into tumor microenvironments, AAV-transduced MSCs could provide an innovative delivery strategy for cancer gene therapies based on the local production of biological agents in the tumor microenvironment. Since such a treatment strategy will require safe and efficient ways of delivering and expressing therapeutic genes in human MSCs, the use of RGD-modified AAV vectors may provide the ideal platform to accomplish genetic manipulation of these cells.
Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer
Authors: Joseph J Bennett, Juri Tjuvajev, Paul Johnson, Mikhail Doubrovin, Timothy Akhurst, Sandeep Malholtra, Trevor Hackman, Julius Balatoni, Ronald Finn, Steven M Larson, Howard Federoff, Ronald Blasberg, Yuman Fong
Journal: Nature Medicine (2001)
Transferring patients: Times have changed
Authors: J. H Turney
Journal: BMJ (1999)

A few moments of peace while awaiting the arrival of a critically ill patient allowed reflection on the changes in the way that patients have been transferred between hospitals. Leeds General Infirmary has provided haemodialysis for patients with acute renal failure since 1956 and the records of this continuous series of several thousand patients have been preserved, providing a wealth of detailed information, not confined to purely medical matters. Because of the scarcity of dialysis facilities—virtually none at all in the early days of …
Abstract 20260: The Effect of Lifestyle Recommendations on Blood Pressure and Blood Pressure Control in Patients With Stage I Hypertension: The Prever Treatment Trial
Authors: Flávio D Fuchs
Journal: Circulation (2014)

Introduction: Lifestyle recommendations are recommended for patients with Stage I hypertension before starting blood pressure-lowering drugs in patients free of cardiovascular disease. The proportion of patients that have blood pressure (BP) controlled with these recommendations was scarcely reported in a clinical context. Hypothesis: To investigate the rate of response to a short-term lifestyle intervention (LsI) in the first phase of a randomized clinical trial. Methods: PREVER prevention is a double blind, multicenter, randomized clinical trial of effectiveness of drug treatment to control hypertension and target organ damage among individuals with hypertension. It was conducted in 22 centers distributed in 10 Brazilian states. Participants were enrolled in the study if they had hypertension (≥140 of systolic blood pressure or ≥90 mmHg of diastolic blood pressure), confirmed in two visits in the clinics of the study, or if they had normal BP but were using BP-lowering agents. BP measurements were carried out using an oscillometric monitor, and anthropometric measurements were taken in duplicate. All participants were submitted to a lifestyle intervention (LsI) phase, which included detailed recommendations to lose weight, to reduce salt, to adopt a DASH-type diet and to practice physical activities. Blood pressure and control of hypertension were verified after three months. In this analysis, we present the results of blood pressure control and variation in the subsample of participants who had BP higher or equal to 140/90 mmHg. Results: 4 867 volunteers were screened and 1 835 evaluated for enrollment. From these, 685 (37%) had BP within stage I hypertension. After three months of intensive LsI, 420 (61.3%) remained with uncontrolled BP, 249 (36.4%) had BP in the 120-139/80-89 mmHg range, and 16 (2.3%) had normal BP. Systolic and diastolic BP reduced from 143.8 ±7.1 to 138.7 ±12.2 mmHg and 90.4 ±5.9 to 87.7 ±8.7, respectively. Conclusion: Approximately 1/3 of patients with Stage I hypertension have blood pressure controlled after three months of lifestyle recommendations to lose weight, reduce salt intake, adopt a DASH diet and practice physical activities.